Sumatriptan for prevention of acute mountain sickness: Randomized clinical trial

Annals of Neurology

Volumn 62, Issue 3, 2007, Pages 273-277

  Jafarian, Sirous ^a   Gorouhi, Farzam ^a   Salimi, Shabnam ^a   Lotfi, Jamshid ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SUMATRIPTAN SUCCINATE; TETRACYCLINE DERIVATIVE;

ADULT; ALTITUDE DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUSHING; HEADACHE; HUMAN; INCIDENCE; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT;

ACUTE DISEASE; ADOLESCENT; ADULT; ALTITUDE SICKNESS; DOUBLE-BLIND METHOD; DRUG ERUPTIONS; ENDPOINT DETERMINATION; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; MOUNTAINEERING; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 34948847615     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21162     Document Type: Article

References (20)

1. Hackett P, Roach RC. High altitude sickness. N Engl J Med 2001;345:107-114.
2. Basnyat B, Murdoch DR. High altitude illness. Lancet 2003;361:1967-1974.
3. Maggiorini M, Bühler B, Walter M, Oelz O. Prevalence of acute mountain sickness in the Swiss Alps. BMJ 1990;301:853-855.
4. Dumont L, Mardirosoff C, Tramer MR. Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ 2000;321:267-272.
5. Perry CM, Markham A. Sumatriptan: an updated review of its use in migraine. Diugs 1998;55:889-922.
6. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. Available at: http://www.wma.net/e/policy/b3.htm. Accessed August 18, 2006.
7. Roach RC, Bartsch P, Hackett PH, et al. The Lake Louise acute mountain sickness scoring system. Hypoxia and molecular medicine. Proceedings of the 8th International Hypoxia Symposium. Burlington, VT: Queen City Printers, 1993:272-274.
8. Dean AG, Yip R, Hoffmann RE. High incidence of mild acute mountain sickness in conference attendees at 10,000 foot altitude. J Wilderness Med 1990;1:86-92.
9. Hackett PH. High altitude cerebral edema and acute mountain sickness: a pathophysiology update. Adv Exp Med Biol 1999;474:23-45.
10. Hackett PH. The cerebral etiology of high-altitude cerebral edema and acute mountain sickness. Wild Environ Med 1999;10:97-109.
11. Hackett PH, Yarnell PR, Hill R, et al. High-altitude cerebral edema evaluated with magnetic resonance imaging: clinical correlation and pathophysiology. JAMA 1998;280:1920-1925.
12. Roach RC, Hackett P. Frontiers of hypoxia research: acute mountain sickness. J Exp Biol 2001;204:3161-3170.
13. Maassen VanDenBrink A, van den Broek RW, de Vries R, et al. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 2000;55:1524-1530.
14. Maassen VanDenBrink A, Reekers M, Bax WA, et al. Coronary side effect potential of current and prospective antimigraine drugs. Circulation 1998;98:25-30.
15. Moore KH, Hussey EK, Shaw S, et al. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Cephalalgia 1997;17:541-550.
16. Utiger D, Eichenberger U, Bernasch D, et al. Transient minor improvement of high altitude headache by sumatriptan. High Alt Med Biol 2002;3:387-393.
17. Bartsch P, Maggi S, Kleger GR, et al. Sumatriptan for high-altitude headache. Lancet 1994;344:1445.
18. Burtscher M, Likar R, Nachbauer W, et al. Ibuprofen versus sumatriptan for high-altitude headache. Lancet 1995;346:254-255.
19. Bolay H, Reuter U, Dunn AK, et al. Intrinsic biain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002;8:136-142.
20. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-1675.